Theravance Biopharma (TBPH) Misses Q1 EPS by 5c, Beats on Revenue

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. AVGO
3. BA
4. CDNS
5. ANT
6. META
7. HOOD
8. SPY
9. STX
10. INTC

Go back to Theravance Biopharma (TBPH) Misses Q1 EPS by 5c, Beats on Revenue

Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025 4:05 PM EDT

YUPELRI® (revefenacin) net sales of $58.3 million, recognized by Viatris, increased 6% versus Q1 20241 TRELEGY net sales of $854M, as reported by GSK, increased 14% versus Q1 20242CYPRESS study open label enrollment nearing completion with final patient expected to be enrolled by late summerQuarter-end cash balance of $131 million, with no debtReaffirming all financial guidance metrics

DUBLIN, May 8, 2025 /PRNewswire/ --... More